Core Insights - LIXTE Biotechnology Holdings, Inc. announced the publication of new pre-clinical data regarding its lead clinical compound, LB-100, which is converted into the active form endothall, a protein phosphatase (PP2A) inhibitor effective in cancer treatment when combined with immunotherapy [1][4] Group 1: Research Findings - The Netherlands Cancer Institute identified an enzyme that mediates the conversion of LB-100 into endothall, suggesting it could serve as a biomarker to identify patients likely to respond to LB-100 [2] - Research from BioPharmaWorks LLC indicated that LB-100 converts into endothall through hydrolysis, although this process is slow under physiological conditions; the enzymatic conversion identified by the Bernards laboratory accelerates this activation within cells [3] Group 2: Clinical Development - Clinical trials for LB-100 are currently underway targeting ovarian cancer and colorectal cancer, with the new pre-clinical data enhancing understanding of LB-100 and endothall's biological availability in patients, aiding in optimizing patient selection for future trials [4] - LIXTE's LB-100 is positioned as a first-in-class PP2A inhibitor, demonstrating good tolerance in cancer patients at doses linked to anti-cancer activity, with potential to improve outcomes for patients undergoing various therapies [4] Group 3: Company Overview - LIXTE is focused on developing and commercializing cancer therapies, with a comprehensive patent portfolio and no known competitors in its new approach to cancer biology, termed activation lethality [4]
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form